Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 186,400 shares, a drop of 41.7% from the March 15th total of 319,700 shares. Based on an average daily volume of 274,600 shares, the […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price target decreased by Benchmark from $9.00 to $4.00 in a research report released on Tuesday morning, Benzinga reports. Benchmark currently has a speculative buy rating on the stock. A number of other analysts have also recently issued reports on PCSA. Oppenheimer cut their price objective on […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price objective reduced by Oppenheimer from $5.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Processa Pharmaceuticals’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at […]